Background: Recent guidelines suggest that, for venous thromboembolism (VTE), standard
doses of apixaban are appropriate in patients with body mass index (BMI)> 40 kg/m2 or> …

Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Abstract Background Direct oral anticoagulants (DOACs) are widely used as therapies for
venous thromboembolism and other cardiovascular diseases. However, routine coagulation …

Background: In patients with venous thromboembolism (VTE), warfarin had been considered
standard of care until the new direct oral anticoagulants (DOACs) were developed. Studies …

Introduction As a result of limited clinical data, guidelines do not recommend the use of non-
vitamin K antagonist oral anticoagulants in patients who weigh> 120 kg or have a body …

Purpose Routine therapeutic drug monitoring of apixaban is currently not recommended but
may however be warranted in some situations and for some patient groups to provide better …

Drug-specific anti-Xa concentrations can be used to assess the presence of drug effects;
however, there is inadequate guidance for clinicians on the interpretation and clinical …

Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

Apixaban is a widely used direct oral anticoagulant that is recommended over warfarin
therapy for many clinical indications. In patients with atrial fibrillation, dose reductions are …

Aim Apixaban is an oral, direct, factor‐X a inhibitor approved for thromboprophylaxis in
patients who have undergone elective hip or knee replacement surgery and for prevention …